# ViaLase, Inc.

> ViaLase, Inc. is a clinical-stage medical technology company in Aliso Viejo, California building the first femtosecond laser designed to treat primary open-angle glaucoma without cutting into the eye. Its ViaLuxe Laser System pairs micron-level, high-definition imaging with a femtosecond laser to perform a noninvasive, image-guided trabeculotomy - branded FLigHT - that creates a drainage channel through the trabecular meshwork to lower intraocular pressure. Founded in 2019 by femtosecond-laser pioneer Tibor Juhasz, the company has raised more than $115 million, earned a CE Mark in Europe, and begun a U.S. IDE clinical trial.

- **Founded:** 2019
- **Headquarters:** Aliso Viejo, California, United States
- **Founders:** Tibor Juhasz (Founder, President & Chief Technology Officer (former CEO))
- **Team size:** ~32 employees
- **Products:** ViaLuxe Laser System, FLigHT Procedure
- **Notable:** Closed $40 million Series C in April 2024, bringing total funding to more than $115 million, Received CE Mark in the EU for the ViaLase Laser to treat adult primary open-angle glaucoma (July 2024), First-in-human study reported no serious adverse events over 24 months and a 34.6% reduction in IOP from baseline

## Products & services

- **ViaLuxe Laser System** — A noninvasive, image-guided femtosecond laser platform that combines a femtosecond laser with micron-level, high-definition imaging to create apertures through the trabecular meshwork and lower intraocular pressure in open-angle glaucoma patients.
- **FLigHT Procedure** — Femtosecond Laser image-guided High-precision Trabeculotomy - a non-incisional, standalone procedure that uses the ViaLuxe system to open a drainage channel through the trabecular meshwork without entering the eye.

## Achievements

- Closed $40 million Series C in April 2024, bringing total funding to more than $115 million
- Received CE Mark in the EU for the ViaLase Laser to treat adult primary open-angle glaucoma (July 2024)
- First-in-human study reported no serious adverse events over 24 months and a 34.6% reduction in IOP from baseline
- Treated first patient in a U.S. IDE clinical trial in December 2025
- Founded by Tibor Juhasz, co-inventor of femtosecond laser ophthalmic surgery and founder of IntraLase and LenSx

## Latest updates

- **2025-12** — ViaLase announced the first patient treated in its U.S. IDE clinical trial evaluating femtosecond laser trabeculotomy for open-angle glaucoma, comparing the procedure to selective laser trabeculoplasty (SLT).
- **2025-07** — Leadership transition: Shawn O'Neil appointed CEO; founder Tibor Juhasz moved to President & CTO; Pete England promoted to Chief Commercial Officer.
- **2024-07** — Received CE Mark in the EU for the ViaLase Laser for adult primary open-angle glaucoma.
- **2024-04** — Closed $40 million Series C financing to advance the first femtosecond laser for glaucoma treatment.

## Links

- Website: https://vialase.com
- LinkedIn: https://www.linkedin.com/company/vialase/
- Instagram: https://instagram.com/vialase_inc

---

Profile page: https://yespress.io/vialase-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-10